Amgen, Servier take options to each other's cardiovascular compounds; deal terminated
Amgen Inc. has licensed US rights to Servier SA’s ivabradine, an If inhibitor that is sold in the EU and over 100 countries across the globe as Procoralan for chronic heart failure and stable angina in patients experiencing increased heart rates.
- Includes Royalty or Profit Split Information
- Product or Technology Swap
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.